Cargando…
Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
Based on compelling preclinical evidence concerning the progress of our novel ruthenium-based metallotherapeutics, we are focusing research efforts on challenging indications for the treatment of invasive neoplasms such as the triple-negative breast cancer (TNBC). This malignancy mainly afflicts you...
Autores principales: | Ferraro, Maria Grazia, Bocchetti, Marco, Riccardi, Claudia, Trifuoggi, Marco, Paduano, Luigi, Montesarchio, Daniela, Misso, Gabriella, Santamaria, Rita, Piccolo, Marialuisa, Irace, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094725/ https://www.ncbi.nlm.nih.gov/pubmed/37047448 http://dx.doi.org/10.3390/ijms24076473 |
Ejemplares similares
-
Safety and Efficacy Evaluation In Vivo of a Cationic Nucleolipid Nanosystem for the Nanodelivery of a Ruthenium(III) Complex with Superior Anticancer Bioactivity
por: Piccolo, Marialuisa, et al.
Publicado: (2021) -
Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems
por: Ferraro, Maria Grazia, et al.
Publicado: (2020) -
Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action
por: Irace, Carlo, et al.
Publicado: (2017) -
Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer
por: Piccolo, Marialuisa, et al.
Publicado: (2019) -
Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity
por: Riccardi, Claudia, et al.
Publicado: (2019)